A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

Clinical trial NCT06445400 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06445400
Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

HER2-positive Breast Cancer

Start date: 2024-06-19
Primary completion: 2025-07-21
Enrollment: 83

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.